|
Key figures – 3rd quarter 2011 |
|
|
|
|
XLS |
|
|
|
|
|
|
|
|
€ million |
Pharma-ceuticals |
Chemicals |
Corporate |
Total |
Change |
|
Total revenues |
1,601.6 |
929.9 |
– |
2,531.6 |
3.8 |
|
Gross margin |
1,315.9 |
535.9 |
– |
1,851.8 |
1.8 |
|
Research and development |
–303.0 |
–68.0 |
– |
–371.0 |
6.4 |
|
Operating result |
191.0 |
166.0 |
–23.8 |
333.3 |
–8.3 |
|
Exceptional items |
– |
–0.1 |
–0.2 |
–0.3 |
– |
|
Earnings before interest and tax (EBIT) |
191.0 |
165.9 |
–23.9 |
333.0 |
–8.4 |
|
EBIT before depreciation and amortization (EBITDA) |
408.2 |
262.1 |
–22.8 |
647.5 |
–7.7 |
|
Return on sales in % |
11.9 |
17.9 |
– |
13.2 |
|
|
Free cash flow |
385.7 |
180.1 |
–84.3 |
481.5 |
– |
|
Underlying free cash flow |
385.8 |
255.4 |
–125.1 |
516.1 |
–8.0 |
|
Underlying free cash flow on revenues (FCR) in % |
24.1 |
27.5 |
– |
20.4 |
|
Print this page